Qnexa: Qnexa is a new drug in clinical trials for glycemic management in people with Type 2 diabetes who are obese.

Qnexa Meets Primary Endpoint By Demonstrating Superior Weight Loss Over Components And Placebo In The 28-Week Equate Study (OB-301)
Qnexa Meets Primary Endpoint By Demonstrating Superior Weight Loss Over Components And Placebo In The 28-Week Equate Study (OB-301) 15 Dec 2008 - 4:00 PST Medicalnewstoday.com VIVUS, Inc. (NASD
Qnexa Meets Primary Endpoint By Demonstrating Superior Weight Loss Over Componen...
Qnexa Reduces Hemoglobin A1c By 1.6% in 56 Weeks
Qnexa Reduces Hemoglobin A1c By 1.6% in 56 Weeks December 12, 2008 Market Watch MOUNTAIN VIEW, Calif., Dec 12, 2008 (BUSINESS WIRE) -- --Treated with Qnexa over One-Year VIVUS (VVUS 6.05, +
http://www.marketwatch.com/news/story/Qnexa-Reduce...
Vivus says obesity drug Qnexa meets goals in trial
Vivus says obesity drug Qnexa meets goals in trial December 11, 2008 Boston.com MOUNTAIN VIEW, Calif.—Drug developer Vivus Inc. said Thursday its obesity drug candidate Qnexa met its goals in
http://www.boston.com/business/healthcare/articles...